Q32 Bio (QTTB) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Q32 Bio (NASDAQ: QTTB):

• 10/1/2026 – Q32 Bio had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 9/28/2026 – Q32 Bio is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $29.00 price target on the stock.
• 9/28/2026 – Q32 Bio is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $29.00 price target on the stock.
• 9/16/2026 – Q32 Bio had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/7/2026 – Q32 Bio was upgraded by Mizuho to “strong-buy”.
• 8/24/2026 – Q32 Bio is now covered by Morgan Stanley. They set an “overweight” rating and a $34.00 price target on the stock.
• 8/21/2026 – Q32 Bio was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 8/7/2026 – Q32 Bio had its “hold (c-)” rating reaffirmed by Weiss Ratings.

Insider Transactions at Q32 Bio

In related news, CFO Lee Kalowski sold 3,972 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $65,776.32. Following the transaction, the chief financial officer directly owned 138,471 shares in the company, valued at approximately $2,293,079.76. The trade was a 2.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shelia M. Violette sold 2,798 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total transaction of $46,334.88. Following the sale, the insider directly owned 127,771 shares in the company, valued at $2,115,887.76. This trade represents a 2.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 16,615 shares of company stock worth $275,144 in the last 90 days. Corporate insiders own 34.46% of the company’s stock.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing therapies for diseases associated with immune dysregulation. The company’s research is aimed at restoring balance in the immune system by targeting biological pathways involved in inflammation, tissue repair and immune regulation.

Q32 Bio’s lead product candidate is bempikibart, also known as ADX-914, a fully human monoclonal antibody designed to inhibit activin A signaling through the activin receptor type IIB pathway.